Download PDF
Thromb Haemost 1988; 60(02): 271-279
DOI: 10.1055/s-0038-1647044
Original Article
Schattauer GmbH Stuttgart

The Effect of Human Recombinant Tissue-Type Plasminogen Activator on Clinical and Laboratory Parameters of Hemostasis and Systemic Plasminogen Activation in the Dog and the Rat

John C Bloom
The Departments of Experimental Pathology and Investigative Toxicology, Smith Kline & French Laboratories, Philadelphia, PA, USA
,
Teresa S Sellers
The Departments of Experimental Pathology and Investigative Toxicology, Smith Kline & French Laboratories, Philadelphia, PA, USA
,
Gary C Gries
The Departments of Experimental Pathology and Investigative Toxicology, Smith Kline & French Laboratories, Philadelphia, PA, USA
,
Eric B Wheeldon
The Departments of Experimental Pathology and Investigative Toxicology, Smith Kline & French Laboratories, Philadelphia, PA, USA
,
Susan R O'Brien
The Departments of Experimental Pathology and Investigative Toxicology, Smith Kline & French Laboratories, Philadelphia, PA, USA
,
Hugh B Lewis
The Departments of Experimental Pathology and Investigative Toxicology, Smith Kline & French Laboratories, Philadelphia, PA, USA
› Author Affiliations
Further Information

Publication History

Received 01 February 1988

Accepted after revision 21 June 1988

Publication Date:
28 June 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The effect of human recombinant tissue-type plasminogen activator (rt-PA) on parameters of hemostasis and systemic plasminogen activation was studied in the dog and rat. Effects on screening coagulation times, fibrinogen concentration, fibrin/fibrinogen degradation products, and plasminogen and α2-anti- plasmin (α2-AP) activities in plasma were examined following single bolus injections of 0.5-5.0 mg/kg, single and repeated 3 hr infusions of 0.75-7.5 mg/kg and 24 hr infusions of 6.0 and 30.0 mg/kg administered intravenously to dogs. Rats receiving single or 14 daily injections of 5.0-30.0 mg/kg i.v. were similarly monitored. Systemic fibrinogenolysis (>50% decrease in fibrinogen, plasminogen or α2-AP values) was observed in dogs receiving ≥1.0 mg/kg as a bolus, ≥3.75 mg/kg (20.8 μg or 1.19 × 104 IU kg−1min−1) as a 3 hr infusion and >6 mg/kg (4.2 μg or 2.42 × 103IU kg−1min−1) as a 24 hr infusion; and in rats treated with bolus injections of 30 mg/kg rt-PA. Clinical and laboratory indications of impaired hemostasis and bleeding (anemia, prolonged coagulation times and post-mortem evidence of hemorrhage) were associated with these effects, which together were dose-dependent and influenced by the rate of infusion. The incidence of major hemorrhage was variable and limited to animals receiving prolonged (24 hr) or repeated infusions.

Keywords

Human recombinant tissue-type plasminogen activator - Dog - Rat - Systemic fibrinogenolysis - Impaired hemostasis
 

  • References

  • 1 Marder VJ, Francis CW. An assessment of regional versus systemic thrombolytic treatment of peripheral and coronary artery thrombosis. In: Progress in Hemostasis and Thrombosis (; Vol 3). Spaet TH. (ed) Grune and Stratton; New York: 1984: 325-356
    Google Scholar
  • 2 Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. J Biol Chem 1982; 257: 2912-2919
    PubMedGoogle Scholar
  • 3 Collen D, Stassen JM, Marafino BJ, Builder S, DeCock F, Ogez J, Tajiri D, Pennica D, Bennett WF, Salwa J, Hoyng CF. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells. J Pharmacol Exp Ther 1984; 231: 146-152
    PubMedGoogle Scholar
  • 4 Matsuo O, Rijken DC, Collen D. Thrombolysis by human tissue plasminogen activator and urokinase in the rabbits with experimental pulmonary embolus. Nature 1981; 291: 590-591
    CrossrefPubMedGoogle Scholar
  • 5 Flameng W, Van de WerfF, Vanhaecke J, Verstraete M, Collen D. Coronary thrombolysis and infarct-size reduction following intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primates. J Clin Invest 1985; 75: 84-90
    CrossrefPubMedGoogle Scholar
  • 6 Carlin G, Einarsson M, Saldeen T. Tissue plasminogen activator effectively lyses intravascular fibrin deposits in the rat lung. In: Progress in Fibrinolysis (; Vol 6.). Davidson JF, Bachman F, Bovier CA, Kruithof EK O. (ed) Churchill Livingstone; Edinburgh: 1983: 471-474
    Google Scholar
  • 7 Korninger C, Matsuo O, Suy R, Stassen JM, Collen D. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis. J Clin Invest 1979; 69: 573-580
    PubMedGoogle Scholar
  • 8 Collen D, Topol EJ, Tiefenbrunn AJ, Gold HK, Weisfeldt ML, Sobel BE, Leinbach RC, Brinker JA, Ludbrook PA, Yasuda I, Bulkley BH, Robinson AK, Hutter Jr AM, Bell WR, Spadaro Jr JJ, Khaw BA, Grossbard EB. Coronary thrombolysis with recombinant human tissue-type plasminogen activator. A prospective randomized placebo-controlled trial. Circulation 1984; 70: 1012-1017
    CrossrefPubMedGoogle Scholar
  • 9 TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial. Phase I findings. N Engl J Med 1985; 312: 932-936
    PubMedGoogle Scholar
  • 10 Verstraete M, Bernard R, Bory M, Brower RW, Collen D, DeBono DP, Erbel R, Huhmann W, Lennane RJ, Lubsen J, Mathey D, Meyer J, Michels HR, Rutsch W, Schartl M, Schmidt W, Uebis R, von Essen R. Randomized trial of intravenous recombinant human tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1985; 1: 842-847
    PubMedGoogle Scholar
  • 11 Sherry S. Appraisal of various thrombolytic agents in the treatment of acute myocardial infarction. Am J Med 1987; 83 (Suppl 2A) 31-46
    PubMedGoogle Scholar
  • 12 Marder VJ. The use of thrombolytic agents. Choice of patient, drug administration, laboratory monitoring. Ann Intern Med 1979; 90: 802-809
    CrossrefPubMedGoogle Scholar
  • 13 Verheijen JH, Mullaart E, Chang GT, Kluft C, Wijngaards G. A simple sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-269
    PubMedGoogle Scholar
  • 14 Von Clauss A. Gerinnungsphysiologische Schnellmethode zu Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246
    CrossrefPubMedGoogle Scholar
  • 15 Soria J, Soria C, Samama M. A plasminogen assay using a chromogenic synthetic substrate: results from clinical work and from studies of thrombolysis. In: Progress in Chemical Fibrinolysis and Thrombolysis (; Vol 3). Davidson JF, Samama MM, Desnoyers PC. (eds) Raven Press; New York: 1978: 337-346
    Google Scholar
  • 16 Edy J, Collen D, Verstraete M. Quantitation of the plasma protease inhibitor antiplasmin with the chromogenic substrate S-2251. In: Progress in Chemical Fibrinolysis and Thrombolysis (; Vol 3). Davidson JF, Samama MM, Desnoyers PC. (eds) Raven Press; New York: 1978: 315-322
    Google Scholar
  • 17 Collen D. On the regulation and control of fibrinolysis. Thromb Haemostas 1980; 43: 77-89
    PubMedGoogle Scholar
  • 18 Marder VJ. Relevance of changes in blood fibrinolytic and coagulation parameters during thrombolytic therapy. Am J Med 1987; 83 (Suppl. 2A) 15-19
    PubMedGoogle Scholar
  • 19 Mueller HS, Rao AK, Forman SA. TIMI Investigators. Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator J Am Coll Cardiol 1987; 10: 479-490
    CrossrefPubMed
  • 20 Califf RM, Stump D, Thornton D, Kereiakes DJ, George BS, Abbottsmith CW, Candella RJ, Boswick JM, Topol EJ. TAMI Study Group. Hemorrhagic complications after tissue plasminogen activator (t-PA) therapy for acute myocardial infarction (abstr). Circulation 1987; 76 (Suppl. IV) IV-1
    PubMedGoogle Scholar
  • 21 Urokinase Pulmonary Embolism Study Group. The urokinase pulmonary embolism trial: a national cooperative study Circulation 1973; 47 (Suppl. II) 1-108
    CrossrefPubMed
  • 22 Collen D, Verstraete M. Alpha2-antiplasmin consumption and fibrinogen breakdown during thrombolytic therapy. Thromb Res 1979; 14: 631-639
    CrossrefPubMedGoogle Scholar
  • 23 Teger-Nilsson AC, Gyzander E, Myrwold H, Noppa H, Olsson R, Wallmo L. Determination of fast-acting plasmin inhibitor (alpha2-antiplasmin) in plasma from patients with tendency to thrombosis and increased fibrinolysis. Hemostasis 1978; 7: 155-157
    PubMedGoogle Scholar
  • 24 Baillie AJ, Sim AK. Activation of the fibrinolytic enzyme system in laboratory animals and in man. A comparative study. Thromb Diath Haemorrh 1971; 25: 499-506
    PubMedGoogle Scholar
  • 25 Niewiarowski S, Latallo Z. Comparative studies of the fibrinolytic systems of sera of various vertebrates. Thromb Diath Haemorrh 1959; 3: 404-417
    PubMedGoogle Scholar
  • 26 Kjaeldgaard A, Larsson B, Astedt B. Immunological comparison between human and rat plasminogen activators in blood and the vessel wall. J Clin Pathol 1984; 37: 1153-1156
    CrossrefPubMedGoogle Scholar
  • 27 Emeis JJ, van den Hoogen CM, Jense D. Hepatic clearance of tissue type plasminogen activator in rats. Thromb Haemostas 1985; 54: 661-664
    PubMedGoogle Scholar
  • 28 Mohler MA, Refino CJ, Chen SA, Chen AB, Hotchkiss AJ. D-phe- pro-arg-chloromethylketone: its potential use in inhibiting the formation of in vitro artifacts in blood collected during tissue-type plasminogen activator thrombolytic therapy. Thromb Haemostas 1986; 56: 160-164
    PubMedGoogle Scholar
  • 29 Verstraete M, Bounameaux H, deCock F, Van der WerfF, Collen D. Pharmacokinetics and systemic fibrinolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. J Pharmacol Exp Ther 1985; 235: 506-512
    PubMedGoogle Scholar
  • 30 Gold HK, Fallon JT, Yasuda T, Leinbach RC, Khaw BA, Newell JB, Guerrero JL, Vislosky FM, Hoyng CF, Grossbard E, Collen D. Coronary thrombolysis with recombinant human tissue-type plasminogen activator. Circulation 1984; 70: 700-707
    CrossrefPubMedGoogle Scholar
  • 31 Silverstein RL, Leung LLK, Harpen PC, Nachman RL. Platelet thrombospondin forms a trimolecular complex with plasminogen and histidine-rich glycoprotein. J Clin Invest 1985; 75: 2065-2073
    CrossrefPubMedGoogle Scholar
  • 32 Miles LA, Plow EF. Binding and activation of plasminogen on the platelet surface. J Biol Chem 1985; 260: 4303-4311
    PubMedGoogle Scholar
  • 33 Adelman B, Michelson AD, Greenberg J, Handin RI. Proteolysis of platelet glycoprotein lb by plasmin is facilitated by plasmin-lysine binding regions. Blood 1986; 68: 1280-1284
    PubMedGoogle Scholar
  • 34 Strieker RB, Wong D, Shui DT, Reyes PT, Shuman MA. Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: effects on surface proteins and platelet aggregation. Blood 1986; 68: 275-280
    PubMedGoogle Scholar
  • 35 Bounameaux H, Stassen J, Seghers C, Collen D. Influence of fibrin and liver blood flow on the turnover and the systemic fibrinogenolytic effects of recombinant tissue-type plasminogen activator in rabbits. Blood 1986; 67: 1493-1497
    PubMedGoogle Scholar